Newer Aspects of Diagnosis and Treatment of Human Fungal Infection

B. Aditya Prakash, Gulab Khedkar, S.p. AkshayInternational Journal of Current Microbiology and Applied Sciences 2019 · DOI

Abstract

Human fungal infections, or mycoses, are witnessing a concerning global rise. While superficial infections affecting the skin and hair are common and often viewed as minor nuisances, invasive fungal pathogens represent a significant and often deadly threat to human health. Susceptibility is driven by a complex interplay of environmental factors, host immunity, and individual risk profiles. Many of these infections can be fatal if not diagnosed early and treated aggressively. This paper reviews the shift toward advanced molecular diagnostics, such as PCR, and explores emerging treatment modalities, including antifungal peptides and vaccines, while addressing the critical issue of antifungal resistance and the misuse of over-the-counter medications.

Introduction: The Rising Threat of Mycoses

In the landscape of infectious diseases, fungi have often been overshadowed by bacteria and viruses. However, the incidence of human fungal infections is increasing, presenting a growing challenge to global healthcare systems. These infections range from superficial conditions like dandruff and ringworm to life-threatening invasive mycoses.

The severity of a fungal infection is often dictated by the host's immune status. While healthy individuals may only suffer from localized skin or nail infections, immunocompromised patients—such as those with diabetes, individuals undergoing chemotherapy, or organ transplant recipients—are at high risk for systemic infections. In these vulnerable populations, fungi that are typically harmless or opportunistic can become pathogenic and lethal.

Environmental and Host Susceptibility

The prevalence of fungal infections is closely tied to the environment. Fungal spores are omnipresent, but certain events can lead to massive exposure. Natural disasters such as earthquakes and floods, or even large-scale construction projects, can aerosolize significant quantities of spores. This often triggers sudden outbreaks of invasive infections like Aspergillosis and mucormycosis.

Beyond environmental exposure, host factors play a decisive role. The rise in metabolic disorders like diabetes and the increasing use of immunosuppressive therapies for cancer and autoimmune diseases have created a larger population of susceptible individuals. Understanding these risk factors is vital for preventative screening and early clinical suspicion.

Diagnostic Evolution: From Traditional Staining to Molecular Precision

Early and accurate diagnosis is the cornerstone of effective fungal management. Historically, clinicians have relied on conventional laboratory methods:

  • Microscopic Examination: Techniques such as KOH (potassium hydroxide) mounting and lactophenol cotton blue staining allow for the visualization of fungal structures.
  • Histopathology: Specialized stains like Hematoxylin and Eosin (H&E) are used to identify fungi within tissue samples.
  • Culture: Growing fungi in specialized media remains a gold standard but is often slow, sometimes taking weeks to yield results.

The paper highlights a significant shift toward molecular diagnostics. Panfungal Polymerase Chain Reaction (PCR) has emerged as a highly sensitive and relatively affordable tool. Unlike cultures, PCR can detect fungal DNA rapidly, allowing for earlier intervention. For deep-seated or systemic infections, radiological imaging such as CT and MRI scans provides essential information regarding tissue involvement and the extent of the disease. However, a current limitation of panfungal PCR is that while it is excellent for detection, it sometimes lacks the specificity required for precise species identification in critical clinical scenarios.

Challenges in Treatment: Resistance and Biofilms

Treating fungal infections is increasingly complicated by two major factors: biological defenses and drug resistance.

The Biofilm Shield

Fungi like Candida and Aspergillus are notorious for their ability to form biofilms. These are complex, multicellular communities encased in a protective extracellular matrix. Biofilms frequently develop on indwelling medical devices, such as central venous catheters or prosthetic joints. This matrix acts as a physical and chemical barrier, making the fungi significantly more resistant to standard antifungal agents compared to their free-floating (planktonic) counterparts.

Antifungal Resistance and OTC Misuse

The clinical utility of standard antifungals, particularly the azole class (e.g., fluconazole), is being eroded by rising resistance. A major contributor to this trend is the "over-the-counter" (OTC) availability and misuse of topical steroid creams. Patients often use these to treat undiagnosed skin rashes. While steroids may temporarily suppress inflammation, they allow the underlying fungal infection to flourish and adapt, eventually leading to chronic, treatment-resistant cases.

Emerging Therapeutic Frontiers

As traditional drugs lose their efficacy, research is pivoting toward novel therapeutic strategies:

  • Antifungal Peptides: Cationic antifungal peptides derived from various plants and animals are being investigated. These peptides target specific fungal virulence factors or disrupt fungal cell membranes, offering a new mechanism of action to bypass existing resistance.
  • Viral Therapies: Similar to the use of bacteriophages against bacteria, researchers are exploring the potential of fungi-targeting viruses to treat infections.
  • Fungal Vaccines: While no human fungal vaccines are currently in routine clinical use, several candidates are in the pipeline, aiming to provide long-term protection for high-risk individuals.
  • Specialized Treatments: For specific conditions like mucormycosis (a severe "black fungus" infection), hyperbaric oxygen therapy is being used as an adjunct treatment. For certain subcutaneous infections, older treatments like potassium iodide still hold clinical value.

Clinical Impact: Corneal Ulcers and Blindness

A particularly pressing clinical issue identified is fungal keratitis (corneal ulcers). Often caused by Aspergillus and Fusarium species, these infections are a leading cause of blindness, especially in agrarian societies like India. The challenge is exacerbated by a critical shortage of effective ophthalmic antifungal formulations, highlighting a significant gap in the current pharmaceutical landscape.

Conclusion and Future Directions

The battle against human fungal infections requires a multi-pronged approach. While molecular techniques like PCR have revolutionized early detection, their specificity for species identification still needs refinement. Future efforts must focus on the development of new drug classes, the implementation of fungal vaccines, and stricter regulation of over-the-counter medications. Ultimately, preserving the efficacy of our current antifungal arsenal while innovating new therapies is essential to reducing the morbidity and mortality associated with these resilient pathogens.

Summary updated

Abstract

Human fungal infections are on the rise. Fungi causing skin infections are common but invasive fungi which are less known appear pathogenic and deadly. Environment, immunity and individual risk factors contribute for its susceptibility. Some of them can be fatal, if not diagnosed early and treated. Advances in molecular techniques help in early diagnosis. New modality of treatment such as antifungal peptides, fungal vaccines are in the pipeline. Improper and “Over the counter” medication must be avoided for the complete cure.
BibTeX
@article{prakash2019newer,
  author = {B. Aditya Prakash and Gulab Khedkar and S.P. Akshay},
  title = {{Newer Aspects of Diagnosis and Treatment of Human Fungal Infection}},
  journal = {International Journal of Current Microbiology and Applied Sciences},
  year = {2019},
  doi = {10.20546/ijcmas.2019.806.224},
}
Figure